Work Here?
Overview
Teiko.bio maps immune profiles to guide immunotherapy and personalized medicine by analyzing interactions between immune and tumor cells to produce actionable data for biopharma clients. Its core offering, the customizable TokuProfile panel with 35+ immune markers, generates an immune fingerprint for each patient to identify predictive markers and monitor treatment impact. The company earns revenue from selling panels and data-analysis services, providing end-to-end immune profiling tailored to drug development and patient stratification. Its goal is to help biopharma companies develop more effective therapies and improve patient outcomes through precise immune data.
About Teiko
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
11-50
Company Stage
N/A
Total Funding
N/A
Headquarters
Salt Lake City, Utah
Founded
2020
Get referred to Teiko
See people who can refer or advise you
Simplify's Take
What believers are saying
- Stingray Therapeutics selected Teiko in July 2026 for its ENPP1 program.
- Teiko expanded Artificial Immunologist across all analysis views in February 2026.
- Cell Reports Medicine published Teiko-generated data on CD38 resistance signatures in 2025.
What critics are saying
- Obsidian, Stingray, and MGH signal traction, but one flagship loss would hurt revenue.
- CellCarta-style portal partnerships commoditize Teiko’s workflow and pressure pricing within 2026.
- If assay noise or biomarker false-positives erode trust, biopharma programs will leave quickly.
What makes Teiko unique
- Teiko pairs CLIA-certified immune monitoring with AI dashboards and regulatory-grade CDISC exports.
- Its TokuKit fixed-sample workflows preserve two-year whole-blood stability, beating live-processing dependencies.
- Validated panels now span 120 markers across human and NHP cytometry assays.
Help us improve and share your feedback! Did you find this helpful?
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -8%2 year growth
↓ -12%Teiko, Inc. is excited to announce the launch of "Download All", a new feature designed to solve the problem of manually accessing gating plots.
Teiko, Inc. is announcing a new upgrade to its AI-powered "Pocket Immunologist" within your dashboards on app.teiko.bio.
San Francisco, CA - July 31, 2025 - Teiko, Inc. has announced the launch of Pocket Immunologist, an AI-powered tool designed to help you quickly interpret high-dimensional cytometry data from your clinical trials.
As part of this study on CD38[+] T cell exhaustion and ICB resistance, Teiko partnered with MGH to analyze 86 melanoma patient blood samples via mass cytometry, uncovering CD38[+] T cell signatures tied to ICB resistance.
Teiko, Inc. has officially released a major upgrade to the Teiko Dashboard: Samples Overview.
Teiko is Hiring for 5 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Teiko
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
11-50
Company Stage
N/A
Total Funding
N/A
Headquarters
Salt Lake City, Utah
Founded
2020
Teiko is Hiring for 5 Jobs on Simplify!
Find jobs on Simplify and start your career today